13 research outputs found
Cellular Cardiomyoplasty: Clinical Application
Myocardial regeneration can be induced with the implantation
of a variety of myogenic and angiogenic cell
types. More than 150 patients have been treated with
cellular cardiomyoplasty worldwide, 18 patients have
been treated by our group. Cellular cardiomyoplasty
seems to reduce the size and fibrosis of infarct scars, limit
postischemic remodelling, and restore regional myocardial
contractility. Techniques for skeletal myoblasts culture
and ex vivo expansion using autologous patient
serum (obtained from plasmapheresis) have been developed
by our group. In this article we propose (1) a total
autologous cell culture technique and procedures for cell
delivery and (2) a clinical trial with appropriate endpoints
structured to determine the efficacy of cellular
cardiomyoplasty
Treatment of heart failure with autologous skeletal myoblasts
The management of patients with heart failure
is a daily challenge for cardiologists and cardiac surgeons.
Pharmacotherapy, atrio-biventricular resynchronization, myocardial
revascularization, valve repair techniques, latissimus
dorsi cardiomyoplasty, acorn cardiac support device, heart
transplantation and mechanical assist devices do not cover all the needs. The recent progress in cellular and molecular biology
allows the development of new therapies for heart failure.
Transplantation of Autologous Cells: One of the most innovative
consists in the transplantation of autologous ex-vivo expanded
cells into the myocardium for heart muscle regeneration.
This approach is called “cellular cardiomyoplasty”
Cellular Cardiomyoplasty: Clinical Application
Myocardial regeneration can be induced with the implantation
of a variety of myogenic and angiogenic cell
types. More than 150 patients have been treated with
cellular cardiomyoplasty worldwide, 18 patients have
been treated by our group. Cellular cardiomyoplasty
seems to reduce the size and fibrosis of infarct scars, limit
postischemic remodelling, and restore regional myocardial
contractility. Techniques for skeletal myoblasts culture
and ex vivo expansion using autologous patient
serum (obtained from plasmapheresis) have been developed
by our group. In this article we propose (1) a total
autologous cell culture technique and procedures for cell
delivery and (2) a clinical trial with appropriate endpoints
structured to determine the efficacy of cellular
cardiomyoplasty
Treatment of heart failure with autologous skeletal myoblasts
The management of patients with heart failure
is a daily challenge for cardiologists and cardiac surgeons.
Pharmacotherapy, atrio-biventricular resynchronization, myocardial
revascularization, valve repair techniques, latissimus
dorsi cardiomyoplasty, acorn cardiac support device, heart
transplantation and mechanical assist devices do not cover all the needs. The recent progress in cellular and molecular biology
allows the development of new therapies for heart failure.
Transplantation of Autologous Cells: One of the most innovative
consists in the transplantation of autologous ex-vivo expanded
cells into the myocardium for heart muscle regeneration.
This approach is called “cellular cardiomyoplasty”